Results 181 to 190 of about 101,301 (311)

Selective vulnerability of GABAergic neurons in chronic migraine. [PDF]

J Headache Pain
Hossain KH, Chuong T, Abad E, Lin J, Xia C, Li M, Chen Y, Arakaki X, Vasudevan A.   +8 more
europepmc   +1 more source

Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN) [PDF]

, 2020
Janet H. Ford, Cristina Tassorelli, Élizabeth Leroux, Shufang Wang, David W. Ayer, Russell Nichols, Holland C. Detke   +6 more
openalex   +1 more source

TEMPOROMANDIBULAR DISORDER IN CHRONIC MIGRAINE

, 2017
Н. В. Латышева, E. G. Filatova, А. С. Платонова   +2 more
openalex   +1 more source

Neuropsychological Functioning in Migraine Headache, Nonheadache Chronic Pain, and Mild Traumatic Brain Injury Patients [PDF]

, 1999
Ben D. Bell, Michelle Primeau, Jerry J. Sweet, Kenneth R. Lofland   +3 more
openalex   +1 more source

Identifying cognitive‐affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Using the fear‐avoidance model (FAM) as a theoretical framework, this study examined the interactions between empirical factors contributing to disability in episodic migraine. It was tested whether pain catastrophizing, fear of attacks, and depressiveness mediate the relationship between pain experience and disability.
Janosch Fox, Charly Gaul, Merle Kuhlencord, Nicolina Peperkorn, Julia Ohse, Joshua Krutzki, Youssef Shiban   +6 more
wiley   +1 more source

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
David Kudrow, Robert S. Croop, Alexandra Thiry, Richard B. Lipton   +3 more
wiley   +1 more source

Exploratory Pain Profiling With Quantitative Sensory Testing (QST) in Episodic and Chronic Migraine. [PDF]

Eur J Pain
van Welie RF, van Welie FC, Trouerbach-Kraan JP, Dahan A, van Velzen M, Terwindt GM.   +5 more
europepmc   +1 more source

How would you manage a 30-year-old woman taking amitriptyline for chronic migraine who wants to conceive?

Tripdatabase
openalex   +1 more source

Multidisciplinary approach to patients with chronic migraine and medication overuse: experience at the Besta Headache Center [PDF]

, 2013
Licia Grazzi
openalex   +1 more source

Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The primary objective of this study was to evaluate opioid and barbiturate utilization before and after the first prescription of the calcitonin gene–related peptide receptor antagonist rimegepant in individuals with migraine. Background Although not recommended in migraine treatment guidelines, opioids and barbiturates are often ...
Noah Rosen, Aaron Jenkins, Karin Hygge Blakeman, Feng Dai, Lucy Abraham, Chelsea Leroue, Josh Brown   +6 more
wiley   +1 more source